Skip to main content
Fig. 8 | Egyptian Journal of Radiology and Nuclear Medicine

Fig. 8

From: "Sinopharm", "Oxford-AstraZeneca", and "Pfizer-BioNTech" COVID-19 vaccinations: testing efficacy using lung CT-volumetry with comparative analysis of variance (ANOVA)

Fig. 8

A 57-year-old female cardiac patient with history of HCV-related liver cirrhosis and had received “Oxford-AstraZeneca” vaccine then got COVID-19 infection. A Axial chest CT cut (lung window) showed bilateral mainly peripheral located heterogeneous ground-glass pneumonic patches with coarse septal thickening “patchy crazy-paving pattern” and large amount of pericardial collection (green arrows). B Coronal chest and upper abdomen CT cuts (mediastinal window) showed peripheral pneumonic patches, pericardial collection, liver cirrhosis and splenomegaly (arrows) C CT-Volumetry of the pathological lung parts averages 809 cc. [D] CT-Volumetry of total lung volume averages 2153 cc. So, 38% of the lung parenchyma was diseased (Score 2)

Back to article page